Re-evaluating the use of growth factors as adjuvant treatment of chronic hepatitis C.
Worman
Howard J
HJ
D017024:Chemotherapy, Adjuvant; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D005602:France; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D014481:United States; D014486:United States Food and Drug Administration
D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor